Biogen (TICKER: BIIB) Benchmark And Performance Data

there are 10 of samples in the benchmark for Biogen in year 2022 in 2022. The total inventory for Biogen was $929,900,000.00 in 2018. The total inventory for Biogen was $902,700,000.00 in 2017. The total inventory for Biogen was $893,400,000.00 in 2015. The total inventory for Biogen was $804,200,000.00 in 2019. The total inventory for Biogen was $804,000,000.00 in 2014. The total inventory for Biogen was $659,003,000.00 in 2013. The total inventory for Biogen was $447,373,000.00 in 2012. The total inventory for Biogen was $1,351,500,000.00 in 2021. The total inventory for Biogen was $1,068,600,000.00 in 2020. The total inventory for Biogen was $1,001,600,000.00 in 2016. The sales, general, and administrative (SGA) for Biogen was $2,674,300,000.00 in 2021. The sales, general, and administrative (SGA) for Biogen was $2,504,500,000.00 in 2020. The sales, general, and administrative (SGA) for Biogen was $2,374,700,000.00 in 2019. The sales, general, and administrative (SGA) for Biogen was $2,232,300,000.00 in 2014. The sales, general, and administrative (SGA) for Biogen was $2,113,100,000.00 in 2015. The sales, general, and administrative (SGA) for Biogen was $2,106,300,000.00 in 2018. The sales, general, and administrative (SGA) for Biogen was $1,946,600,000.00 in 2016. The sales, general, and administrative (SGA) for Biogen was $1,933,900,000.00 in 2017. The sales, general, and administrative (SGA) for Biogen was $1,712,100,000.00 in 2013. The sales, general, and administrative (SGA) for Biogen was $1,277,465,000.00 in 2012. The sales, general, and administrative (SGA) for Biogen was $$2,404,000,000 in 2022. The revenue volatility for Biogen was 12.94% in 2022. The market capitalization for Biogen was $51,628,857,000.00 in 2012. The market capitalization for Biogen was $41,571,231,000.00 in 2013. The market capitalization for Biogen was $41,246,280,000.00 in 2020. The market capitalization for Biogen was $40,258,744,000.00 in 2019. The market capitalization for Biogen was $39,876,868,795.00 in 2018. The market capitalization for Biogen was $38,448,000,000.00 in 2017. The market capitalization for Biogen was $37,221,045,328.00 in 2021. The market capitalization for Biogen was $35,268,240,000.00 in 2014. The market capitalization for Biogen was $31,063,500,000.00 in 2015. The market capitalization for Biogen was $29,612,088,000.00 in 2016. The market capitalization for Biogen was $$35,796,000,000 in 2022. The gross revenue for Biogen was $9,703,300,000.00 in 2014. The gross revenue for Biogen was $6,932,200,000.00 in 2013. The gross revenue for Biogen was $5,516,461,000.00 in 2012. The gross revenue for Biogen was $14,377,900,000.00 in 2019. The gross revenue for Biogen was $13,452,900,000.00 in 2018. The gross revenue for Biogen was $13,444,600,000.00 in 2020. The gross revenue for Biogen was $12,273,900,000.00 in 2017. The gross revenue for Biogen was $11,448,800,000.00 in 2016. The gross revenue for Biogen was $10,981,700,000.00 in 2021. The gross revenue for Biogen was $10,763,800,000.00 in 2015. The gross revenue for Biogen was $$10,173,000,000 in 2022. The gross margin for Biogen was $28.52% in 2022. The days sales outstanding for Biogen was 74 days in 2022. The days payable outstanding for Biogen was 87 days in 2022. The days of inventory for Biogen was $216 in 2022. The cost of goods sold (COGS) for Biogen was 22.39% in 2022. The cost of goods sold (COGS) for Biogen was $857,700,000.00 in 2013. The cost of goods sold (COGS) for Biogen was $545,494,000.00 in 2012. The cost of goods sold (COGS) for Biogen was $2,109,700,000.00 in 2021. The cost of goods sold (COGS) for Biogen was $1,955,400,000.00 in 2019. The cost of goods sold (COGS) for Biogen was $1,816,300,000.00 in 2018. The cost of goods sold (COGS) for Biogen was $1,805,200,000.00 in 2020. The cost of goods sold (COGS) for Biogen was $1,630,000,000.00 in 2017. The cost of goods sold (COGS) for Biogen was $1,478,700,000.00 in 2016. The cost of goods sold (COGS) for Biogen was $1,240,400,000.00 in 2015. The cost of goods sold (COGS) for Biogen was $1,171,000,000.00 in 2014. The cost of goods sold (COGS) for Biogen was $$2,278,000,000 in 2022. The cash to cash cycle time for Biogen was 203 in 2022. The annual percentage growth rate of Biogen was 0.07% in 2022. Biogen in its benchmark peer group, had rank 9 for gross revenue in 2022. Biogen in its benchmark peer group, had rank 8 for cash to cash cycle time in 2022. Biogen in its benchmark peer group, had rank 8 days for days sales outstanding in 2022. Biogen in its benchmark peer group, had rank 8 days for days of inventory in 2022. Biogen in its benchmark peer group, had rank 3 for cost of goods sold as a percent of revenue in 2022. Biogen in its benchmark peer group, had rank 1 for sales growth in 2022. Biogen headquarters region is East. Biogen has ticker symbol BIIB. Biogen has the following profile: Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.. Biogen has primary indstury Drug Manufacturers - General. Biogen had a $$27,177,000,000 gap between actual performance and next performance rank for gross revenue in competitive benchmarking in 2022. Biogen had Organon, and Eli Lilly, and AbbVie, and Pfizer, and Bristol-Myers Squibb, and Amgen, and Gilead Sciences, and Biogen, and Johnson & Johnson, and Merck benchmark peer companies for its SIC code in 2022. Biogen had 87 days gap between actual performance and next performance rank for days of inventory in competitive benchmarking in 2022. Biogen had 8,725 number of employees in 2022. Biogen had 8 days gap between actual performance and next performance rank for days sales outstanding in competitive benchmarking in 2022. Biogen had 59.55% gap between actual performance and next performance rank for cost of goods sold as a percent of revenue in competitive benchmarking in 2022. Biogen had 2.05% gap between actual performance and next performance rank for gross margin in competitive benchmarking in 2022. Biogen had 2.00% gap between actual performance and next performance rank for sales volatility in competitive benchmarking in 2022. Biogen had 120 days gap between actual performance and next performance rank for cash to cash in competitive benchmarking in 2022. Biogen had 0.00% gap between actual performance and next performance rank for sales growth in competitive benchmarking in 2022. Biogen can reduce overall cost by $$6,323,000,000 by improving both COGS and SGA to next benchmark tier in 2022. Biogen can reduce inventory with practices including SKU Reduction in 2022. Biogen can reduce inventory with practices including Reduce Manufacturing Latency in 2022. Biogen can reduce inventory with practices including Forecast Accuracy in 2022. Biogen can reduce inventory with practices including Demand Shaping in 2022. Biogen can reduce days sales outstanding with practices including in 2022. Biogen can increase sales revenue by $$27,177,000,000 improving sales performance to next benchmark tier in 2022. Biogen can increase revenue growth by $$0 by improving growth performance to next benchmark tier in 2022. Biogen can increase overall revenue by $$27,177,000,000 by improving both growth and sales performance to next benchmark tier in 2022. Biogen can increase days payables outstanding with practices including Strategic Sourcing in 2022. Biogen can increase days payables outstanding by $84,000,000 days by increasing days payables outstanding to next benchmark tier in 2022. Biogen can improve total financial performance by $$36,245,000,000 by improving revenue, costs, and working capital in 2022. Biogen can decrease overall working capital by $$2,745,000,000 by improving inventory, payables and receivables to next benchmark tier in 2022. Biogen can decrease inventory days by $2,425,000,000 days by reducing inventory days to next benchmark tier in 2022. Biogen can decrease days sales outstanding by $237,000,000 days by reducing days sales outstanding to next benchmark tier in 2022. Biogen can accelerate revenue growth practices including in 2022. 82 days was the measured parity or middle performance level for cash to cash cycle time in Biogen's peer group in 2022. 79 days was the measured superior or top ten performance level for days of inventory in Biogen's peer group in 2022. 68 days was the measured advantage or top third performance level for cash to cash cycle time in Biogen's peer group in 2022. 66 days was the measured parity or middle performance level for days sales outstanding in Biogen's peer group in 2022. 61 days was the measured advantage or top third performance level for days sales outstanding in Biogen's peer group in 2022. 6.73% was the measured superior or top ten performance level for sales volatility in Biogen's peer group in 2022. 56 days was the measured superior or top ten performance level for days sales outstanding in Biogen's peer group in 2022. 37.46% was the measured superior or top ten performance level for gross margin in Biogen's peer group in 2022. 37 days was the measured superior or top ten performance level for cash to cash cycle time in Biogen's peer group in 2022. 26.85% was the measured parity or middle performance level for cost of goods sold as a percent of revenue in Biogen's peer group in 2022. 22.98% was the measured advantage or top third performance level for cost of goods sold as a percent of revenue in Biogen's peer group in 2022. 21.84% was the measured superior or top ten performance level for cost of goods sold as a percent of revenue in Biogen's peer group in 2022. 14.35% was the measured parity or middle performance level for sales volatility in Biogen's peer group in 2022. 129 days was the measured parity or middle performance level for days of inventory in Biogen's peer group in 2022. 100 days was the measured advantage or top third performance level for days of inventory in Biogen's peer group in 2022. 10.93% was the measured advantage or top third performance level for sales volatility in Biogen's peer group in 2022. 0.03% was the measured superior or top ten performance level for sales growth in Biogen's peer group in 2022. 0.00% was the measured advantage or top third performance level for sales growth in Biogen's peer group in 2022. -0.01% was the measured parity or middle performance level for sales growth in Biogen's peer group in 2022. $33.59% was the measured advantage or top third performance level for gross margin in Biogen's peer group in 2022. $30.58% was the measured parity or middle performance level for gross margin in Biogen's peer group in 2022. $$95,482,000,000 was the measured superior or top ten performance level for gross revenue in Biogen's peer group in 2022. $$58,423,000,000 was the measured advantage or top third performance level for gross revenue in Biogen's peer group. $$37,350,000,000 was the measured parity or middle performance level for gross revenue in Biogen's peer group in 2022.